Alecensa
Alecensa ingredients
| Active ingredient | Strength |
|---|---|
| Alectinib Hydrochloride | 150 mg/1 |
What Alecensa is used for
The FDA lists the approved uses on the official label (below). In the EU, alectinib is approved as Alecensa for:
Adjuvant treatment of resected non small cell lung cancer (NSCLC) Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK positive NSCLC at high risk of recurrence (see section 5.1 for selection criteria).Treatment of advanced NSCLCAlecensa as monotherapy is indicated for the first line treatment of adult patients with ALK positive advanced NSCLC.Alecensa as monotherapy is indicated for the treatment of adult patients with ALK positive advanced NSCLC previously treated with crizotinib.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Alecensa
- Generic name
- Alectinib hydrochloride
- Made by
- Genentech, Inc.
- Forms
- Capsule
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA208434
- On the US market since
- 2015
Official information
- Alecensa prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Alectinib hydrochloride)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Alecensa?
Alecensa (Alectinib hydrochloride) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Alecensa?
Alecensa contains Alectinib Hydrochloride (150 mg/1).
Is Alecensa approved in Europe?
The same active substance is approved in the EU as Alecensa.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA